NOVEL COMPOSITIONS

Abstract: A pharmaceutical composition comprising a compound of formula (I): in which R is optionally substituted phenyl; C₃₋₈ cycloalkyl; C₅₋₈ cycloalkenyl; C₁₋₈ alkyl which may be straight or branched; C₂₋₈ alkenyl which may be straight or branched; 5- or 6- mem­ bered heterocyclyl; or optionally substituted phenyl C₁₋₄ alkyl, each of Y and Z, which may be the same or different, is oxygen or sulphur; and X is -CH₂- or oxygen; and at least one other an­ thelmintically active compound. The use of such compositions in human and veterinary medicine is also described.

Description: NOVEL COMPOSITIONS The present invention relates to pharmaceutical compositions, in particular to compositions having broad spectrum anthelmintic activity, and their use in human and veterinary medicine. Accordingly, the present invention provides a pharmaceutical composition comprising a compound of formula (I): EMI1.1 in which R is optionally substituted phenyl, C38 cycloalkyl, C58 cycloalkenyl, C18 alkyl which may be straight or branched, C28 alkenyl which may be straight or branched, 5- or 6- membered heterocyclyl, or optionally substituted phenyl C1-4 alkyl; Y and Z, which may be the same or different, represent oxygen or sulphur: and X is -CH2- or oxygen; and at least one other anthelmintically active compound. Compounds of formula (I) are claimed in European Patent Application No. 84107989.0 (Publication Number 0 134 984 Al). Suitably, the said other anthelmintically active compound has anthelmintic activity against nematodes, especially against hook worms and ascarid worms in man or domestic animals, for example dogs and cats. Suitable compounds with anthelmintic activity are the benzimidazole anthelmintics for example fenbendazole; macrocyclic lactones for example in an avermectin; or piperazine, morantel, pyrantel or levamisole. Some of the anthelmintically active compounds form salts; it will be understood therefore that the composition of the present invention may include a pharmaceutically acceptable salt of these compounds. Suitable salts are the acid addition salts, for example the pharmaceutically acceptable salts of acids such as hydrochloric, hydrobromic, hydroiodic, nitric, sulphuric, citric, tartaric and pamoic acids. A preferred compound is pyrantel or a pharmaceutically acceptable salt thereof, in particular pyrantel pamoate. When used herein the term ''pharmaceutical1 includes the term ''veterinary'' and the term ''pharmaceutically'' includes the term "veterinarily". Compounds of formula (I) have an asymmetric carbon atom (marked by an asterisk) and may therefore exist in at least two stereoisomeric forms. The present invention encompasses all isomers of the compounds of formula (I) whether pure or admixed with other isomers in any proportion. When R is optionally substituted phenyl, the phenyl group may be substituted with up to three groups selected from halogen, C16 alkyl, C16 alkoxy, nitro, amino, mono-or-di-C1-6 alkylamino, and hydroxy. When R is heterocyclyl, it may be a 5 or 6-membered saturated or unsaturated group containing up to three hetero-atoms selected from oxygen, sulphur and nitrogen. It will be appreciated that unsaturatd heterocyclyl groups suitably include aromatic heterocyclyl groups. The term ''halogen'' refers to fluorine, chlorine, bromine and iodine. A preferred R group is cyclohexyl. Compounds of formula (I) may be produced by cyclising a compound of formula (II): EMI3.1 in which X is as defined in formula (I); R1 is hydrogen, a protecting group or a group EMI3.2 wherein R and Y are as defined in formula (I); and R2 is C13 alkyl or hydrogen; and thereafter, if necessary: i) removing any protecting group R1 and replacing it with a group EMI3.3 or ii) when R1 is hydrogen, replacing it with a group EMI4.1 and/or iii) converting the compound of formula (I) thus formed, wherein Z is oxygen, to a compound of formula (I) wherein Z is sulphur, by treatment with a thionation reagent. As used herein the term ''thionation reagent' denotes a reagent capable of converting the group EMI4.2 into the group EMI4.3 A preferred thionation reagent is Lawesson's reagent, i.e. 2,4-bis(4-methoxyphenyl)-1,3-dithia-2, 4-diphosphetane -2,4-disulphide, as described, for example, in Synthesis, 941 (1979), Tetrahedron 35, 2433 (1979) and Tetrahedron Letters, 21, 4061 (1980). In the above process, replacement of the group R1Eafter the compound of formula (II) has been cyclised] by the group EMI4.4 in which Y is sulphur, may be carried out using a dithioic ester of formula EMI4.5 wherein R is hereinbefore defined and R4 is C1-6 alkyl. As used herein the term 'protecting group' refers to a group which is stable under the cyclisation reaction conditions but which may readily be removed after the cyclisation is complete. A typical example of such a protecting group is benzyl, which may be removed by catalytic hydrogenation, for instance using a palladium catalyst in a suitable solvent, for example ethanol. Examples of R2 are methyl, ethyl, propyl and hydrogen; preferably R2 is hydrogen. Compounds of formula (II) may be cyclised by treatment with an acid catalyst, and conveniently an acid such as polyphosphoric acid may be used. The reaction may be conducted at elevated temperature, such as 1000C or greater, for instance at about 1800C. Alternatively, concentrated sulphuric acid may be used, in which case the reaction is carried out at a lower temperature , for example from - 100C to + 400C. Compounds of formula (II) wherein R2 is hydrogen may be produced by reducing the corresponding imide of formula (III): EMI5.1 wherein X, and R1 are as hereinbefore defined. The reduction is effected using a suitable hydride reducing agent, such as sodium borohydride in a suitable solvent such as a lower alkanol, preferably ethanol. Compounds of formula (11) wherein R2 is alkyl may be produced by conventional methods, such as those outlined in the papers of W.Speckamp et al Efor example, see Tetrahedron 31, 1437 (1975)1. Compounds of formula (III) may be produced according to Scheme I, using conventional reagents, such as those shown in the scheme. Scheme I EMI6.1 In Scheme I, R3 is a protecting group or a group EMI7.1 in which Y is as hereinbefore- defined, and X is as hereinbefore defined. It will be appreciated that the compounds of formula (IIIa) in Scheme I have the same structure as compounds of formula (III) as hereinbefore defined except when R1 in the latter is hydrogen. Compounds of formula (III) wherein R1 is hydrogen may be produced by removing a protecting group R3 from a compound of formula (IIIa). Compounds of formula (I) have anthelmintic activity especially against tapeworm such as Taenia taeniaeformis and Dipylidium caninum. The pharmaceutical composition of the invention is of use in the treatment of helminthiasis of the human or non-human animal body, and particularly for treating tapeworm and/or nematode infestations of domestic animals, especially dogs and cats and farm animals. Accordingly, the present invention also provides a method of treating helminthiasis, particularly tapeworm and/or hema'tod infestations, in human or domestic animals, which method comprises administering to the human or domestic animal in need thereof an anthelmintically effective amount of a pharmaceutical composition of the invention. Suitably, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or vehicle; the particular carrier used depending upon the chosen means of administration. Suitable carriers are those used conventionally in the art for the particular means of administration. Thus, for example, if the pharmaceutical composition is to be formulated as a bolus, tablet or capsule, the pharmaceutically acceptable carrier will be chosen from the usual range of lubricants, dispersants, binders, fillers and the like. For administration to humans, especially children, the pharmaceutical composition may suitably be formulated as a syrup including suitable colouring and/or flavouring agents. Such syrups are conveniently presented in unit or multi-dose containers. For veterinary use the pharmaceutical composition may be formulated as a dispersion or a solution of the composition in a suitable vehicle for use with an oral doser (a well known item of veterinary or farm equipment, comprising a liquid reservoir, a mouthpiece adapted for insertion into animals' mouths, and a pump mechanism whereby unit doses can be ejected from the reservoir through the mouthpiece). Conveniently the pharmaceutical composition may be adminstered from the oral doser in the form of an aqueous suspension. Alternatively, the carrier included in the composition of the invention will be an oil or water based cream to ensure homogeneity of the unit doses administered. The pharmaceutical composition may also be added to the animal feed or drinking water so that the animal ingests an appropriate quantity of the pharmaceutical composition with its diet. In this case the composition is conveniently presented as a premix containing several doses. The pharmaceutical composition may also be formulated for injection. In such cases the pharmaceutical composition chosen is suitably dissolved or suspended in a suitable pharmaceutically acceptable vehicle, for example water, propylene glycol or glycerol formal. Suitably the pharmaceutical composition comprises sufficient material to provide a dose of from 0.01 to 250 mg of the compound of formula (I) per kg of animal body weight per dose, more suitably 0.1 to 50 mg/kg per dose. The said other anthelmintically active compounds are present in the pharmaceutical composition in an amount sufficient to provide a dose within a range conventional for the particular compound. The following examples illustrate the invention Preparation XI 1- (3-Phenylpropyl ) -4-benzyl-2, 6-piperazinedione 3-Phenyl-l-propylamine (3.63g) and N-benzyliminodiacetic acid (6.0g) was mixed and heated to 2000C under a nitrogen atmosphere. The mixture was stirred at this temperature for lh, cooled and purified by column chromatography (six2, 40-600C petroleum ether/chloroform) to give the title material as a pale orange liquid (5.53g, 64%). Preparation X2 1- (3-Phenylpropyl ) -4-benzyl-2-bydroxy-6-oxopiperazine Saturated aqueous sodium bicarbonate solution (20ml) was added to a solution of l-(3-phenylpropyl)-4benzyl-2,6-piperazinedione (5. 35g) in ethanol (170ml) at SOC and sodium borohydride (1.23g) added portionwise to the resulting mixture at 50C over a period of 2h. The mixture was stirred for a further lh at 50C and the solvent removed in vacuo. Water (50ml) was added, and the mixture extracted with dichloromethane (3 x 50 ml), the extracts washed with brine and dried (MgSO4). Evaporation of the solvent gave the title compound as a white solid (4.36g, 81%) Preparation X3 2-Benzyl-4-oxo-1, 2,3,4,6,7,8,1 2b-octahydropyrazino- ±2, 1-a)±23benzazepine 1- (3-Phenylpropyl ) -4-benzyl-2-hydroxy-6- oxopiperazine (2.6g) and polyphosphoric acid (53g) were mixed, heated at 180 C and maintained at this temperature for 3/4h. The mixture was cooled to 600C and water (200ml) added. The mixture was cooled, basified with sodium hydroxide solution, and extracted with chloroform (3 x 50ml). The solvent was evaporated and the product crystallised from diethyl ether to give the title compound (0.78g, 32%) m.p. 125-80C. Preparation X4 4-Oxo-1,2,3,4,6,7,8,12b-octahydropyrazino[2,1-a][2]- benzazepine Hydrogenolysis of 2-benzyl-4-oxo-1,2,3,4,6,7,8, 12b-octahydropyrazino[2,1-a][2]benzazepine (1.39g) in solution in ethanol (40ml) by treatment with hydrogen at 450C and atmospheric pressure in the presence of a palladium on charcoal catalyst (0.3g) gave the title compound (0.6g, 618). Preparation X5 Resolution of 2H-4-oxo-1, 2,3,4,6,7,8, 12b-octahydropyr- azino ±2, l-a)±2]benzazepine (+) 2H-4-oxo-1,2,3,4,6,7,8,12b-octahydropyrazino ±2, 1-a] E2]benzazepine (3.2g, 0.0148 mol) was dissolved in methanol (35ml) and a solution of (-) tartaric acid (2.45g, 0.0163 mol) in methanol (140ml) added. The mixture was heated on a steam bath, filtered whilst hot, and allowed to cool. White crystals were deposited, and these were filtered, and recrystalised from methanol (250ml) to give the (-) tartarate salt of (-) 2H-4-oxo-1,2,3,4,6,7,8,12b-octahydropyrazino [2,1-a][2] benzazepine (a)22 - 1490 (H20). D A solution of this salt in water gave, upon basification with ammonium hydroxide and extraction with chloroform, the free base (-) 2H-4-oxo-1,2,3,4,6,7,8,12b-octahydropyrazino ±2, 1-a] [2] benzazepine as a white solid ( )22 - 2210 (CH30H). D Similarly, using (+) tartaric acid in place of (-) tartaric acid was obtained: (+) 2H-4-oxo-1,2,3,4,6,7,8,12b-octahydropyrazino E2,l-a] [2] benzazepine (+) tartrate, ( )22 +1530 (H20) (Found C; 55.7, H; 6.1, N; 7.4%. D C17H22N207 requires C; 55.7, H; 6.0, N; 7.6%), and (+) 2H-4-oxo-1,2,3,4,6,7,8,12b-octahydropyrazino ±2,l-a] [2] benzazepine free base (a)22 +2120 'CH30H). D Preparation l 2-(Cyclohexylcarbonyl)-4-oxo-l,2,3,4,6,7,8,12b- octahydropyrazino2,l-alC23benzazepine Cyclohexanoyl chloride (0.34g) was added to a solution of 4-oxo-1,2,3,4,6,7,8,12b-octahydropyrazino ±2,1-a]E2] benzazepine (0.5g) in chloroform (20ml ethanol free) maintained at 0 C and triethylamine (0.26g) added. The mixture was maintained at OOC for 30 min then at room temperature for 5h. The solution was washed with, first, dilute hydrochloric acid and secondly with sodium bicarbonate solution. The chloroform solution was dried (MgS04) and evaporated. The residue was recrystallised from chlorform/40-600C petroleum ether to give white crystals of the title compound (0.48 g, 64%) m.p. 187-900C. Found: C: 73.2, H: 7.7, N: 8.4% C20H26N202 requires C: 73.6, H: 8.0, N: 8.6% Preparation 2 Pyrantel pamoate Pyrantel pamoate may be prepared as described in Belgian Patent No.658987. Preparations 3-5 The following tabulated preparations were carried out in analogous fashion to that described in Preparation 1. EMI14.1 EMI14.2 <SEP> ru <tb> <SEP> Microanalytical <SEP> Data <tb> Prepara- <SEP> m.p. <tb> tion <SEP> No. <SEP> R <SEP> oC <SEP> Calculated <SEP> Found <tb> <SEP> C <SEP> H <SEP> N <SEP> C <SEP> H <SEP> N <tb> <SEP> t <tb> <SEP> 3 <SEP> C <SEP> 154-155 <SEP> 73.05 <SEP> 7.74 <SEP> 8.97 <SEP> 72.31 <SEP> 7.43 <SEP> 8.88 <tb> <SEP> 7.43 <SEP> 8.88 <tb> <SEP> 4 <SEP> C <SEP> 160-165 <SEP> 74.08 <SEP> 8.29 <SEP> 8.23 <SEP> 74.27 <SEP> 8.30 <SEP> 8.14 <tb> <SEP> 5 <SEP> t <SEP> 149-150 <SEP> 74.04 <SEP> 7.46 <SEP> 8.63 <SEP> 73.97 <SEP> 7.46 <SEP> 8.61 <tb> Preparation 6 2-(Cyclohexylcarbonyl)-4-oxo-1,2,3,6,7, 12b-hexahydropyrazino El, 2-d) (1, 4]benzoxazepine 4-Oxo-l,2,3,6,7,12b-hexahydropyrazino ±1,2-d] [1,4] benzoxazepine (0.9 g) and triethylamine (1 g) were dissolved in dichloromethane (20 ml), cooled in ice and cyclohexanoyl chloride (0.7 g, 1.1 equiv.) added. The mixture was stirred at room temperature for 3 h, then washed with dilute aqueous hydrochloric acid, followed by dilute aqueous ammonia solution. Evaporation of the dichloromethane gave an oil which was purified by column chromatography (SiO2/chloroform) and crystallised from ether/400-600 petroleum ether to give white crystals of the title compound m.p. 92-30; found: C, 69.53t H, 7.40; N, 8.54% C19H24N203 requires C, 69.49; H, 7.37; N, 8.53%. Preparation 7 (+) 2-(Cyclohexylcarbonyl)-4-oxo-1,2,3,4,6,7,8,12b- octahydropyrazino C2,1-a}C2] benzazepine The title compound was obtained by the method of preparation 1 using (+) 2H-4-oxo-1,2,3,4,6,7,8,12b- octahydropyrazino (2,1-a] C23 benzazepine in place of the racemic compound. The product was purified by column chromatography (SiO2/CHCl3). (a)22 +410 (CH30H). D Preparation 8 (-) 2-(Cyclohexylcarbonyl)-4-oxo-1,2,3,4,6,7,8,12b- octahydropyrazino±2, 1-a) ±2] benzazepine The title compound was obtained as a white solid by the procedure outlined in preparation 1 using (-) 2H-4-oxo1,2,3,4,6,7,8,12b-octahydropyrazino ±2,1-a] [2] benzazepine in place of the racemic compound. The product was purified by column chromatography (SiO2/CHCl3), (&alpha;)êê -42 (CH30H). D The following are examples of pharmaceutical compositions of the invention. Example 1 %(w/w) 2- (Cyclohexylcarbonyl ) -4-oxo- 1,2,3,4,6,7,8,12b-octahydropyrazino 25 [2,1-a][2]benzazepine Pyrantel pamoate 75 Example 2 %(w/w) 2-(Cyclopentylcarbonyl)-4-oxo 1,2,3,4,6,7,8,12b-octahydropyrazino 25 [2,1-a][2]benzazepine Pyrantel pamoate 75 Example 3 %(w/w) 2-(Cycloheptylcarbonyl)-4-oxo1,2,3,4,6,7,8,12b-octahydropyrazino 25 [2,1-a][2]benzazepine Pyrantel pamoate 75 Example 4 % (w/w) 2- (1 -Cyclohexenyl ) carbonyl-4-oxo- 1,2,3,4,6,7,8,12b-octahydropyrazino 25 [2,1-a][2]benzazepine Pyrantel pamoate 75 example 5 %(w/w) 2-(Cyclohexylcarbonyl)-4-oxo 1,2,3,6,7,12b-hexahydropyrazino 25 [1,2-d][1,4]benzoxazepine Pyrantel pamoate 75 Example 6 %(w/w) (-) 2-(Cyclohexylcarbonyl)-4-oxo <RTI ID=19.1> 1,2,3,4,6,7,8,12b-octahydropyrazino 25 ±2, l-a]±2]benzazepine Pyrantel pamoate 75 Pharmacological Data a) A cat infected with Toxascaris leonina and Dipylidium caninum was orally dosed with sufficient of the composition of Example 1 (formulated as gelatin capsule) to give a dose of 5 mg/kg of 2-(cyclohexylcarbonyl)-4-oxo-l,2, 3,4,6, 7,8,12b octahydropyrazino C2,1-a]benzazepine and 15 mg/kg of pyrantel pamoate. This treatment completely cleared the animal of both infections. b) Three cats infected with Toxocara cati in addition to an infection of Dipylidium caninum, Taenia taeniaeformis and a combination of the two respectively were dosed orally with gelatine capsules containing a mixture of 2-(cyclohexylcarbonyl)-4-oxo-l, 2,3,4,6,7,8, 1 2b-octahydropyrazino± 2,1-a] ±2 ]benzazepine and pyrantel pamoate to give a dose of 7.5 mg/kg of the former and 55 mg/kg of the latter. All three cats were completely cleared of their parasitic infections.

Claims: CLAIMS A 1. A pharmaceutical composition comprising a compound of formula (I): EMI20.1 in which R is optionally substituted phenyl, C38 cycloalkyl, C5-8 cycloalkenyl, C1-8 alkyl which may be straight or branched, C28 alkenyl which may be straight or branched, 5- or 6- membered heterocyclyl, or optionally substituted phenyl C14 alkyl; Y and Z, which may be the same or different, represent oxygen or sulphur; and X is -CH2- or oxygen; and at least one other anthelmintically active compound, together with a pharmaceutically acceptable carrier. 2. A pharmaceutical composition as claimed in claim 1 in which in the compound of formula (I) R is C38 cycloalkyl or C58 cycloalkenyl. 3. A pharmaceutical composition as claimed in claim 1 or claim 2 in which in the compound of formula (I) Y and Z are both oxygen. 4. A pharmaceutical composition as claimed in any one of the preceding claims in which the other anthelmintically active compound is selected from the group consisting of fenbendazole, avermectin, piperazine, morantel, pyrantel, levamisole and pharmaceutically acceptable salts thereof. 5. A pharmaceutical composition as claimed in any one of claims 1 - 4 in which the other anthelmintically active compound is pyrantel or a pharmaceutically acceptable salt thereof. 6. A pharmaceutical composition as claimed in any one of claims 1 - 5 in which the other anthelmintically active compound is pyrantel pamoate. 7. A pharmaceutical composition comprising 2-(cyclohexylcarbonyl)-4-oxo-l,2,3,4,6,7,8,12b octahydropyrazino±2,l-a]benzazepine and pyrantel or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier. 8. A pharmaceutical composition as claimed in claim 7 in which pyrantel is in the form of the pamoate salt. 9. A pharmaceutical composition as claimed in any one of claims 1 - 8, adapted for oral administration. 10. A pharmaceutical composition as claimed in claim 9 in the form of a bolus, tablet or capsule. 11. A method of treating helminthiasis in humans or domestic animals, which method comprises administering to the human or domestic animal in need thereof an anthelmintically effective amount of a pharmaceutical composition as claimed in claim 1. 12. The use of a compound of formula (I) as claimed in claim 1 and at least one other anthelmintically active compound for the manufacture of a medicament for the treatment of helminthiasis in human and domestic animals.

Inventors: BREWER, MALCOLM DAVID, DORGAN, RODERICK JOHN, ELLIOTT, RICHARD LEONARD, MAMALIS, PATRICK, MANGER, BRIAN RICHARD
Applicants: BEECHAM GROUP PLC
Application year: 1985
Main classification: A61K31
IPC codes: C07D487, A61P33, A61K31, C07D498